Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATG4B | Q9Y4P1 | 20/20 | 1.00 |
| ▸ | CDK2 | P24941 | 2/20 | 1.00 |
| ▸ | GSK3A | P49840 | 2/20 | 1.00 |
| ▸ | GSK3B | P49841 | 2/20 | 1.00 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 1/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 1/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.73 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.73 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29526825 | 0.94 | ATG4B (0.88) | ATG4BCDK2GSK3AGSK3BRPS6KB1 | |
| SCHEMBL14401217 | 0.90 | ATG4B (0.82) | ATG4BCDK2GSK3AGSK3BRPS6KB1 | |
| SCHEMBL10152517 | 0.87 | ATG4B (0.79) | ATG4BCDK2GSK3AGSK3BRPS6KB1 | |
| SCHEMBL18529259 | 0.87 | ATG4B (1.00) | ATG4BCDK2GSK3AGSK3BRPS6KB1 | |
| SCHEMBL18529276 | 0.85 | ATG4B (1.00) | ATG4BCDK2GSK3AGSK3BRPS6KB1 | |
| SCHEMBL18529257 | 0.85 | ATG4B (1.00) | ATG4BCDK2GSK3AGSK3BRPS6KB1 | |
| SCHEMBL18529275 | 0.85 | ATG4B (1.00) | ATG4BCDK2GSK3AGSK3BRPS6KB1 | |
| SCHEMBL1394887 | 0.85 | ATG4B (1.00) | ATG4BCDK2GSK3AGSK3BRPS6KB1 | |
| SCHEMBL18541826 | 0.83 | ATG4B (1.00) | ATG4BCDK2GSK3AGSK3BRPS6KB1 | |
| SCHEMBL17616919 | 0.82 | GSK3B (0.70) | ATG4BCDK2GSK3AGSK3BRPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1602 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070916-A | Application of arteannuin with double functions in promoting liver cell maturation and relieving liver lipid metabolism dysfunction | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | 2026-05-22 | — | — | CN | claimed |
| EP-4743565-A2 | CYTOKINE ENCODING LENTIVIRAL VECTORS AND USES THEREOF FOR MAKING TUMOR INFILTRATING LYMPHOCYTES | Iovance Biotherapeutics, Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| CN-122038284-A | Method for inducing differentiation of anterior foregut endoderm cells to form lung progenitor cells and application thereof | 广州国家实验室 | 2026-05-15 | — | — | CN | claimed |
| WO-2025251988-A9 | REAGENT COMBINATION OR KIT FOR CONSTRUCTING EMBRYOID AND USE THEREOF | 广州国家实验室 | 2026-05-15 | — | — | WO | claimed |
| CN-122038274-A | Method for inducing differentiation and maturation of alveolar organoids and application thereof | 广州国家实验室 | 2026-05-15 | — | — | CN | claimed |
| US-20260132380-A1 | Hepatocyte Expansion Methods | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2026-05-14 | — | — | US | claimed |
| US-20260132374-A1 | Compositions and Methods for Efficient Amplification of Retinal Progenitors Cells | SORBONNE UNIVERSITE (FR) | 2026-05-14 | — | — | US | claimed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-12618045-B2 | Automated method for preparing retinal pigment epithelium cells | CENTRE D'ETUDE DES CELLULES SOUCHES (CECS) (FR) | 2026-05-05 | — | — | US | claimed |
| US-20260117173-A1 | METHOD FOR MESENCHYMAL PHENOTYPE REVERSION IN PRIMARY HUMAN CORNEAL ENDOTHELIAL CELLS | UNIVERSITÀ DEGLI STUDI DI MODENA E REGGIO EMILIA (IT) | 2026-04-30 | — | — | US | claimed |
| EP-2126045-A2 | EARLY MESODERM CELLS, A STABLE POPULATION OF MESENDODERM CELLS THAT HAS UTILITY FOR GENERATION OF ENDODERM AND MESODERM LINEAGES AND MULTIPOTENT MIGRATORY CELLS (MMC) | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2009-12-02 | — | — | EP | claimed |
| US-20090041863-A1 | Use of GSK3 inhibitors in combination with radiation therapies | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-02-12 | — | — | US | claimed |
| WO-2008094597-A2 | EARLY MESODERM CELLS, A STABLE POPULATION OF MESENDODERM CELLS THAT HAS UTILITY FOR GENERATION OF ENDODERM AND MESODERM LINEAGES AND MULTIPOTENT MIGRATORY CELLS (MMC) | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2008-08-07 | — | — | WO | claimed |
| EP-1845094-A1 | METHOD OF TUMOR SUPPRESSION AND EVALUATION OF ANTICANCER AGENT BASED ON GSK3 BETA INHIBITORY EFFECT | National University Corporation Kanazawa University (JP) | 2007-10-17 | — | — | EP | claimed |
| US-20060204980-A1 | Colorectal cancer therapies | MASSACHUSETTS, UNIVERSITY OF | 2006-09-14 | — | — | US | claimed |
| US-20060194854-A1 | New 2-substituted - 1,3-thiazole compounds | ASTRAZENECA AB (SE) | 2006-08-31 | — | — | US | claimed |
| WO-2006034207-A2 | USE OF GSK3 INHIBITORS IN COMBINATION WITH RADIATION THERAPIES | VANDERBILT UNIVERSITY (US) | 2006-03-30 | — | — | WO | claimed |
| US-20050119321-A1 | 2-substituted-1,3-thiazole compounds | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | US | claimed |
| EP-1499601-A1 | NEW 2-SUBSTITUTED -1,3-THIAZOLE COMPOUNDS | AstraZeneca AB (SE) | 2005-01-26 | — | — | EP | claimed |
| WO-2003089419-A1 | NEW 2-SUBSTITUTED -1,3-THIAZOLE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-10-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618045-B2 | Automated method for preparing retinal pigment epithelium cells | WNT3A, BRSK1, BMP2K | ATG4B 3177/4885CDK2 545/4885GSK3A 20/4885 |
| US-20260117173-A1 | METHOD FOR MESENCHYMAL PHENOTYPE REVERSION IN PRIMARY HUMAN CORNEAL ENDOTHELIAL CELLS | GSK3B, GSK3A, EPCAM | ATG4B 3240/4885CDK2 1506/4885GSK3A 2/4885 |
| US-20260132374-A1 | Compositions and Methods for Efficient Amplification of Retinal Progenitors Cells | IGF1R, NR2E3, TFEB | ATG4B 2957/4885CDK2 648/4885GSK3A 22/4885 |
| US-20260132380-A1 | Hepatocyte Expansion Methods | HGF, CTNND1, MET | ATG4B 1227/4885CDK2 448/4885GSK3A 11/4885 |
| US-20060194854-A1 | New 2-substituted - 1,3-thiazole compounds | NR3C2, NR4A2, NR0B1 | ATG4B 3617/4885CDK2 1630/4885GSK3A 3544/4885 |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | WNT3A, GSK3B, GSK3A | ATG4B 548/4885CDK2 601/4885GSK3A 3/4885 |
| US-20050119321-A1 | 2-substituted-1,3-thiazole compounds | NR3C2, NR4A2, NR4A3 | ATG4B 3788/4885CDK2 1597/4885GSK3A 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.